Evidence map›Paper›PMID 42799020›Full record

ArticleACS omega2026

Data-Driven Approach for Bioreactor Monitoring and Prediction in Monoclonal Antibody Production.

Kadeejathul Kubra, Munawar A Shaik

Abstract read
In one paragraph

Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Kadeejathul KubraDepartment of Chemical and Petroleum Engineering, College of Engineering, UAE University, Al Ain P.O. Box 15551, UAE.ORCID https://orcid.org/0009-0009-2471-1492
Munawar A ShaikDepartment of Chemical and Petroleum Engineering, College of Engineering, UAE University, Al Ain P.O. Box 15551, UAE.ORCID https://orcid.org/0000-0002-4364-483X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The upstream biopharmaceutical processes of monoclonal antibody (mAb) production generate high-dimensional and irregularly sampled time-series data with many missing values, which can limit the robustness and reusability of data-driven models. In this study, a data-driven workflow has been developed for a previously published industrial fed-batch dataset for the mAb production process. The workflow provides comprehensive data analysis from data cleaning and imputation through model benchmarking and interpretability to enable soft sensing and predictive modelling of mAb bioreactors. Initially, the missing value imputation and their evaluation were carried out using eight supervised machine learning (ML) regressors with temporally engineered time-dependent features. Light gradient boosting machine (LightGBM) provided the best imputed data among the eight ML models and was used as the imputation model for all the variables. Compared with a previously published dual-hybrid imputation method, the LightGBM-based imputation pipeline preserved all observed measurements exactly. It reproduces more accurately both marginal distributions and the multivariate geometry of the data. Using this imputed dataset, thirty-four single and stacked ML models were benchmarked for two industrially relevant tasks. These were used for (i) pointwise soft sensing of the mAb titer using concurrent process variables and (ii) early-stage prediction of final mAb titer using data from 1-7 days. Nonlinear tree-based ensembles achieved test R

Identifiers

PMID42799020
PMCPMC13613435

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.